Madrigal PharmaceuticalsMDGL
Recorded

Madrigal Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Akash TewariGlobal Head of Biopharmaceutical Research

Good morning, everyone. Day two of our Jefferies Healthcare Conference in London. Really, it's been a tremendous success so far, and again, so grateful for the attendance. My name's Akash Tewari. I lead our pharmaceutical and biotech research efforts internally within the firm. I have the pleasure of hosting the Madrigal management team. Bill, why don't I hand it off to you for some introductory remarks, and we'll get started?

Bill SiboldCEO and Director

Great. First of all, thanks for having us here. This is a highlight of the year, one of the highlights of the year for us. We are off to an objectively outstanding launch after 10 quarters. We recently reported $431 million for the third quarter. You annualize that's a $1.7 billion run rate, $1.1 billion in sales through Q3. We become a blockbuster in 10 quarters, and we're really just at the very beginning. Remember, the context is for the last five quarters, we've been competing against one of the biggest companies in the world with one of the largest products of all time, WEGOVY, and it hasn't had any impact that we can see. We have a market that is growing 30% this year, which now takes it up to over 530,000 patients.

Bill SiboldCEO and Director

When we first started, we were at 315,000 patients as the potential market. We've built a pipeline in a short period of time, which we think is the industry-leading pipeline. Over 55,850 patients on drug. I mean, just as you go metric by metric, we are off to a great start. Maybe the final piece I'll say is that it's still a disease that's only 10% diagnosed and 10% penetrated. We're at 1% of what we think will be one of the largest specialty markets in the industry. Firing on all cylinders, great quarter, great prospects ahead.

Akash TewariGlobal Head of Biopharmaceutical Research

Understood. I'm going to start with, not a focus on the quarter, but actually on a board addition that you had. You recently had John Reed, who is sitting R&D head at J&J, and on the executive committee there, join your board. Again, everyone's focused on the launch, outcomes, but I feel like that's quite interesting. It's not something we see quite often. Can you talk about what John really brings to the board, how he helps you as you think about stratifying and really owning MASH on a long-term perspective? Again, why him, in terms of a board addition?

Bill SiboldCEO and Director

Yeah. Well, it is very, pardon me, rare to have an acting, sitting head of R&D, fortunately not conflicted. I have worked with John in the past, and I think he is just a highest quality character. He has experiences which range all the way from research through development, but also at senior levels in companies. As a CEO and as a leadership team and as a board, what do you want? You want wisdom. You want people that have seen it. They know what good looks like. They know what great looks like. They know what bad looks like. They can help you think through complicated problems and win. John brings that. He is a seasoned executive who, look, I have known him, as I said, for years. I trust John. I think part of the reason John joined is because he sees this as one of those markets where somebody can definitively win.

Bill SiboldCEO and Director

A lot of times, companies have a successful product, and then they go on to their next indication. Rarely do you have the ability to assemble all the science, and John is a very science-focused guy, where you can assemble all the science and take a leadership role in a space, drive the science, create the science, and benefit from the science. I think that is what makes us very unique. Also, with a big company like J&J, you are conflicted out of a lot of areas that you can work. There are not so many people still focused on MASH, so that allows him in. It adds a very seasoned, experienced person who can guide us. He also is great from that R&D translational medicine.

Bill SiboldCEO and Director

We have a pipeline that is mostly preclinical, though we have some phase I, phase II assets as well. So, it is the whole package. We are thrilled to have him, and so far it has only been one board meeting he has been at, but brought tremendous value.

Akash TewariGlobal Head of Biopharmaceutical Research

Understood. Now, again, before we get into the quarter, I remember one of the first times we met, you talked about this dynamic of believers of MASH, or I will call it NASH, or non-believers, right? The sense that, well, who knows if this market is actually real? You had this kind of threat of GLP-1s that are going to enter and what would the increments be? Then you also have outcomes, right? So, like that, and some of these questions are pending. Some of them we might have answers to. So, if you were a preacher and you were going to say, "I want you to be a believer of NASH," what are the truths, let us say, that you would have to convince people of? Now, 10 plus quarters into launch, what do you feel like you have externally shown people on what this opportunity actually is?

Bill SiboldCEO and Director

Yeah. Look, we've been fighting a lot of bear theses for a long time. I've just passed my third-year anniversary. First of all, you heard people talking about this being a big disease, prevalent disease. People are talking about millions and millions of patients. Interesting. More important is it's a serious disease. Number one cause of liver transplants for women in America, soon to be number one overall.

Bill SiboldCEO and Director

That is a serious disease. I've worked with a lot of serious diseases. Rarely have they ended in death or transplant. That's where this disease takes you. I think that there's a little bit of a misunderstanding about that as well, how serious it can be, and I think people are starting to understand that. The question was, is it a market? Are there patients? We didn't subscribe to the theory of, say that there's millions of patients, get 1% market share, it's a blockbuster, invest in us. I don't think that's the right way to do it. I think that's too vague. I don't think that's actionable. I don't think you can create a launch plan around that. That's why we took a very strict interpretation. Who was diagnosed, who was F2, F3, and who was at the practices that we were calling on, 14,000 prescribers?

Bill SiboldCEO and Director

That's how we got to 315,000 patients. That was through a rigorous using epi, using claims databases, using market research, and using our target list. So, we found that there were 315,000 patients. That's where we focused. We created a specialty launch around it, that we had done a lot of pharmacoeconomic work, products cost-effective. We could become a specialty launch. What we've seen is that there are patients that are getting on drug and benefiting to a large degree, 55,850, greater than 55,850. So, is there a market? The answer is yes, right? The unmet need and prescribers are willing to prescribe. That's kind of question number one. Is there a future? Yes. Market growth is 30% this year, over 30% this year, so that 315 is going to end up likely over 600,000 this year. So, there's growth. Do GLP-1s make a difference?

Bill SiboldCEO and Director

Yes, they help with market growth. That is fantastic, right? I think Novo's efforts have helped make awareness greater, especially in the primary care world, and we've benefited from that. However, they haven't had any impact that we can see on our growth, and the reason being is that profiles matter, and how you launch matters. If you look at WEGOVY versus REZDIFFRA from a clinical trial perspective, efficacy looks quite similar. In the real world, it's a different story, though, because you have to get to a high enough dose and stay on it long enough, and we know that that's where GLP-1s have their problems. So, GLP-1s, that bear thesis went away.

Bill SiboldCEO and Director

I think as you look ahead to the future now, it's hard to find a market with the fundamentals as good as this, starting with a high unmet need, significant enough patient population, a profile that looks great with REZDIFFRA. I often call it the Holy Grail profile, a once-a-day pill that's effective, safe, well-tolerated. Now, before anyone else has assembled their pipeline, we have, we think, most the mechanisms, almost all the mechanisms that we would want to put in combination with REZDIFFRA as a foundational therapy. To me, the setup is great, and the fact that we've demonstrated this much progress in 10 quarters, and we're on the runway that we're on, really validates the opportunity, and the numbers that I've given shows a great future.

Akash TewariGlobal Head of Biopharmaceutical Research

Understood. It's interesting. I feel like if you had said, "GLP-1s had no impact on our launch two years ago," a lot of people would have been very skeptical. I think the empirical data, when we look at your patient ads, supports that. You have potentially some other MOAs that are entering the market, but you said several times profile. I'm going to ask you to call your shot again. So you're having consistent patient ads, 6,000 to 7,000 a quarter.

Bill SiboldCEO and Director

Steadily adding. Steadily adding. It is the way we refer to it.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day